| [1] |
Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends-an update[J]. Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
|
| [2] |
De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy[J]. Circ Res,2010,106(1):35-46.
|
| [3] |
Miller K, Cortes J, Hurvitz SA, et al. HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated,anthracycline-naive, HER-2-positive, locally advanced/metastatic breast cancer[J]. BMC Cancer,2016,16(1):352-363.
|
| [4] |
贾勇圣,佟仲生. 人表皮生长因子受体2 阳性早期乳腺癌患者新辅助治疗和辅助治疗的研究进展[J/CD]. 中华乳腺病杂志(电子版),2015,9(6):387-393.
|
| [5] |
Addetia K, DeCara JM. Cardiac complications of HER2-targeted therapies in breast cancer[J]. Curr Treat Options Cardiovasc Med,2016,18(6):36.
|
| [6] |
Zelnak AB, Wisinski KB. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches? [J]. Cancer,2015,121(1):17-24.
|
| [7] |
Alba E, Albanell J, de la Haba J,et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial[J]. Br J Cancer,2014,110(5):1139-1147.
|
| [8] |
Yu AF, Yadav NU, Lung BY, et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer[J]. Breast Cancer Res Treat,2015,149(2):489-495.
|
| [9] |
曾化桂. HER-2 阳性乳腺癌抗HER-2 药物治疗的心脏毒性研究进展[J]. 临床肿瘤学杂志,2017,22(4):362-368.
|
| [10] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol,2013,14(8):741-748.
|
| [11] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med, 2011, 365(14):1273-1283.
|
| [12] |
Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel(ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol,2012,30(31):3792-3799.
|
| [13] |
Aitelhaj M,Lkhouyaali S,Rais G,et al. Cardiac safety of the adjuvant trastuzumab in a Moroccan population: observational monocentric study of about 100 patients[J]. BMC Res Notes,2013,6:339.
|
| [14] |
Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial [J]. J Clin Oncol, 2008, 26(8):1231-1238.
|
| [15] |
Russo G, Cioffi G, Gori S, et al. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer[J]. J Cardiovasc Med (Hagerstown),2014,15(2):141-146.
|
| [16] |
Piotrowski G, Gawor R, Bourge RC, et al. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study[J]. Pharmacol Res,2013,78:41-48.
|
| [17] |
Lange SA, Ebner B, Wess A, et al. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy[J]. Clin Res Cardiol,2012,101(6):415-426.
|
| [18] |
刘卫东,叶英响,杨洁红.曲妥珠单抗对心肌细胞损害作用的实验研究[J].实用药物与临床,2015,18(5):532-535.
|
| [19] |
Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2012, 23 Suppl 7:vii155-166.
|